Mometasone furoate/formoterol combination therapy increases frequency of days/nights free of short-acting β2-agonist use

Methods All studies enrolled subjects (≥12y) with persistent asthma not well controlled on inhaled corticosteroids (ICS): study 1 (n=746 subjects with moderate persistent asthma randomized to 26wk MF/F-100/10μg, MF-100μg, F-10μg, or placebo twice daily [BID]); study 2 (n=781 subjects with moderate persistent asthma randomized to 26wk MF/F-200/10μg, MF-200μg, F-10μg, or placebo BID); study 3 (n=728 subjects with severe persistent asthma randomized to 12wk MF/F-400/10μg, MF/F-200/ 10μg, or MF-400μg BID). All studies included a 2-3wk MF BID run-in: P04073 (100μg), P04334(200μg), P04431 (400μg). Percentage of SABA-free days/nights was a predefined secondary endpoint in all studies.